Hypertension,Essential
Conditions
Keywords
Fimasartan, Essentail hypertension
Brief summary
The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide, based on fimasartan. (Stage 1). Also, this study will evaluate major cardiovascular events, long-term blood pressure control, and the safety by follow-up of those who consent to the extended study for about 2 years (96 weeks).(Stage 2)
Detailed description
This study will be conducted as a prospective observational study in about 600 domestic medical institutions, which are at least clinical level. The investigator will enroll those who have essential hypertension and meet the inclusion and exclusion criteria after obtaining voluntary written consent for participation in the study and use of personal information. This study is a non-interventional observational study and is based on decisions by the investigator about the choice of antihypertensive drugs, the period of treatment, and the medication change status etc. During this study period, the scope of data to be collected is as follows: * Demographic information * Disease information (historical diseases and concomitant diseases ) * Physical measurements and vital signs * Blood pressure Central Blood pressure and hemodynamic values (if applicable) * Information on antihypertensive drugs and other concomitant medications * Adverse drug reaction(ADR) and serious adverse drug reactions(SADR) related to fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide * Information on cardiovascular events (Only if subjects are in long term follow-up) * Death information (Only if subjects are in long term follow-up)
Interventions
None listed
Sponsors
Boryung Pharmaceutical Co., Ltd
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria: 1. Patients who voluntarily consent on the informed consent form and understand the study's purpose, methods, and so on 2. Males and females over the age of 19 3. Patients who have been diagnosed with essential hypertension and plan to be treated with fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide If the patient is applicable, one of the following; * If the patients have severe hypertension, stage 2 or higher(sit SBP ≥ 160 mmHg or sit DBP ≥ 100 mmHg), or high-risk hypertension (The cardiovascular risk score of the 2018 hypertension treatment guidelines by the Korean Society of Hypertension is applied.) The patients have never been treated with antihypertensive drugs for essential hypertension. * If the patients are on concomitant administration of fimasartan/amlodipin and hydrochlorothiazide for essential hypertension or, If the patients are on concomitant administration of a fimasartan/hydrochlorothiazide combination and amlodipine for essential hypertension * If the patients have a blood pressure of sitSBP ≥ 140 mmHg or sitDBP ≥ 90 mmHg even though they have been treated with antihypertensive drugs for essential hypertension 4. The patients who understand this study and are available to participate in this study until the end of the study period with a cooperative attitude. *
Exclusion criteria
1. The patients who are suspected of having secondary hypertension or confirmed to have secondary hypertension 2. The patients who are contraindicated to taking fimasartan complex according to the drug labelling 3. The patients who are currently participation in another clinical trials (Drugs or medical devices) The patients who took an investigational drug within 12 weeks of the enrollment date However, the following patients can participate in this study: The patients who are currently enrolled in non-interventional clinical studies or who are being followed up on after the administration of investigational drugs has ended. 4. The patients who are not suitable for this study by the investigators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The blood pressure control rate | Week 12 | The blood pressure control rate (\< 140/90 mmHg)(Systolic and Diastolic) at Week 12 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The blood pressure control rate | Week 8 | The blood pressure control rate (\< 140/90 mmHg) at Week 8 |
| The target blood pressure control rate | Week 12 | The target blood pressure control rate (\< 140/90 mmHg) at Week 12 |
| Change in central systolic pressure(CSP) and Central diastolic pressure(CDP) | Week 12 | Change in central systolic pressure(CSP) and Central diastolic pressure(CDP) at Week 12 from baseline (Only the subjects who measured the central blood pressure) |
| Control rate of The Blood pressure control rate | Week 36, Week 48, Week 96 | Control rate of The Blood pressure control rate(\< 140/90 mmHg) at Week 36 , 48 and 96 |
| The incidence rate of major cardiovascular event(MACE) | Week 96 | The incidence rate of major cardiovascular event(MACE) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse drug reactions(ADR) related to fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide | Week 12, Week 96 | Adverse drug reactions(ADR) related to fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide (From the baseline to Week 12, From the baseline to Week 96) |
| Serious Adeverse Drug Reaction(Serious ADR) related to fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide | Week 12, Week 96 | Serious Adeverse Drug Reaction(Serious ADR) related to fimasartan/amlodipine or fimasartan/amlodipine/hydrochlorothiazide (From the baseline to Week 12, From the baseline to Week 96) |
Countries
South Korea
Contacts
Primary ContactMyungSook Hong
Backup ContactJiYeon Kim
Outcome results
None listed